Rep. Amy L. Grant excused from HB5492 vote on 12-month hormone therapy insurance mandate

Rep. Amy L. Grant (R-47th) was listed as excused on HB5492—a measure mandating insurance coverage for 12-month prescription hormone therapy—during the 104th General Assembly session on May 31, 2026, according to the Illinois House. The House passed the bill by a 75-39 vote.

The bill summary describes it as: "PRESCRIPTION HORMONE THERAPY."

The analysis below, informed by the bill’s full text, offers interpretive clarification of the legislation’s key elements.

Starting Jan. 1, 2028, this legislation directs most Illinois individual and group health insurance policies—as well as state employee and Medicaid coverage—to include up to a 12-month supply of prescribed hormone therapy and related self-administration materials, all provided at once following an in-network provider’s order. It further specifies the therapies covered (excluding glucagon-like peptide-1 drugs), permits insurers to apply certain drug management tools and restricts additional late-year refills past the 12-month allotment, and obligates carriers to arrange out-of-network access if needed. Pharmacists and other dispensers, except in specific circumstances, must fill up to a 12-month supply at the patient’s request.

The legislative record for HB5492 cited the action: 'Senate Floor Amendment No. 2 House Concurs.'

Grant earned a BS from the University of Pittsburgh in 1980.

Elected in 2023, the Republican Grant represents Illinois’ 47th House District, having succeeded Deanne Mazzochi.

The legislative process in Illinois involves a series of steps including initial introduction, committee review, floor consideration, and votes in both chambers before a bill proceeds to the governor for signature or veto. Working on a biennial calendar, the General Assembly sees thousands of bills submitted each session, with only a select number advancing to become law.